Pharmacokinetics and pharmacodynamics of dextromethorphan: clinical and forensic aspects

References

• Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wieling J, Hekster YA, Burger DM. 2005. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther. 78(6):664–674.
   PubMed Web of Science ®Google Scholar
• Abanades S, Peiro AM, Farre M. 2004. Club drugs: old medicines as new party drugs. Med Clin (Barc). 123(8):305–311.
   PubMed Web of Science ®Google Scholar
• Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U. 2010. Assessment of activity levels for CYP2D6* 1, CYP2D6* 2, and CYP2D6* 41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther. 88(5):643–651.
   PubMed Web of Science ®Google Scholar
• Agnich LE, Stogner JM, Miller BL, Marcum CD. 2013. Purple drank prevalence and characteristics of misusers of codeine cough syrup mixtures. Addict Behav. 38(9):2445–2449.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Malik M, Teselink J, Lanctôt KL, Herrmann N. 2019. Current agents in development for treating behavioral and psychological symptoms associated with dementia. Drugs Aging. 36(7):589–605.
   PubMed Web of Science ®Google Scholar
• Aiyer R, Mehta N, Gungor S, Gulati A. 2018. A systematic review of NMDA receptor antagonists for treatment of neuropathic pain in clinical practice. Clin J Pain. 34(5):450–467.
   PubMed Web of Science ®Google Scholar
• Al-Jenoobi FI, Al-Thukair AA, Alam MA, Abbas FA, Al-Mohizea AM, Alkharfy KM, Al-Suwayeh SA. 2015. Effect of Curcuma longa on CYP2D6-and CYP3A4-mediated metabolism of dextromethorphan in human liver microsomes and healthy human subjects. Eur J Drug Metab Pharmacokinet. 40(1):61–66.
   PubMed Web of Science ®Google Scholar
• Aumatell A, Wells RJ. 1993. Chiral differentiation of the optical isomers of racemethorphan and racemorphan in urine by capillary zone electrophoresis. J Chromatogr Sci. 31(12):502–508.
   PubMed Web of Science ®Google Scholar
• Aytha SK, Dannaram S, Moorthy S, Sharma A. 2013. A case of acute psychosis secondary to coricidin overdose. Prim Care Companion CNS Disord. 15(6): PCC.13l01549. DOI:10.4088/PCC.13l01549
   PubMedGoogle Scholar
• Bailey B, Daneman R, Daneman N, Mayer JM, Koren G. 2000. Discrepancy between CYP2D6 phenotype and genotype derived from post-mortem dextromethorphan blood level. Forensic Sci Int. 110(1):61–70.
   PubMed Web of Science ®Google Scholar
• Baldo BA. 2018. Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol. 92(8):2457–2473.
   PubMed Web of Science ®Google Scholar
• Banerji S, Anderson IB. 2001. Abuse of Coricidin HBP cough & cold tablets: episodes recorded by a poison center. Am J Health Syst Pharm. 58(19):1811–1814.
   PubMed Web of Science ®Google Scholar
• Banken JA, Foster H. 2008. Dextromethorphan: an emerging drug of abuse. Ann N Y Acad Sci. 1139(1):402–411.
   PubMed Web of Science ®Google Scholar
• Barnhart JW, Massad EN. 1979. Determination of dextromethorphan in serum by gas chromatography. J Chromatogr. 163(4):390–395.
   PubMed Web of Science ®Google Scholar
• Battin DG, Varkey TA. 1982. Neuropsychiatric manifestations of bromide ingestion. Postgrad Med J. 58(682):523–524.
   PubMed Web of Science ®Google Scholar
• Bem JL, Peck R. 1992. Dextromethorphan. An overview of safety issues. Drug Saf. 7(3):190–199.
   PubMed Web of Science ®Google Scholar
• Bi S, Zhou H, Wu J, Wang Y. 2018. Interaction of dextromethorphan hydrobromide with DNA: multispectral, voltammetric, and molecular docking technology. J Biomol Struct Dyn. 36(5):1154–1160.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Popik P. 2000. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-d-aspartate (NMDA) antagonists. Drug Alcohol Depend. 59(1):1–15.
   PubMed Web of Science ®Google Scholar
• Bjoraker KJ, Swanson MA, Coughlin CR, Christodoulou J, Tan ES, Fergeson M, Dyack S, Ahmad A, Friederich MW, Spector EB, et al. 2016. Neurodevelopmental outcome and treatment efficacy of benzoate and dextromethorphan in siblings with attenuated nonketotic hyperglycinemia. J Pediatr. 170:234–239.
   PubMed Web of Science ®Google Scholar
• Boland DM, Rein J, Lew EO, Hearn WL. 2003. Fatal cold medication intoxication in an infant. J Anal Toxicol. 27(7):523–526.
   PubMed Web of Science ®Google Scholar
• Bolser DC. 2006. Current and future centrally acting antitussives. Respir Physiol Neurobiol. 152(3):349–355.
   PubMed Web of Science ®Google Scholar
• Bortolotti F, Bertaso A, Gottardo R, Musile G, Tagliaro F. 2013. Dextromethorphan/levomethorphan issues in a case of opiate overdose. Drug Test Anal. 5(9–10):781–784.
   PubMed Web of Science ®Google Scholar
• Braga PC, Fossati A, Vimercati MG, Caputo R, Guffanti EE. 1994. Dextrorphan and dextromethorphan: comparative antitussive effects on guinea pigs. Drugs Exp Clin Res. 20(5):199–203.
   PubMedGoogle Scholar
• Brown C, Fezoui M, Selig WM, Schwartz CE, Ellis JL. 2004. Antitussive activity of sigma-1 receptor agonists in the guinea-pig. Br J Pharmacol. 141(2):233–240.
   PubMed Web of Science ®Google Scholar
• Brown GR, McLaughlin K, Vaughn K. 2018. Identifying and treating patients with synthetic psychoactive drug intoxication. J Am Acad PAs. 31:1–5.
   Google Scholar
• Bryner JK, Wang UK, Hui JW, Bedodo M, MacDougall C, Anderson IB. 2006. Dextromethorphan abuse in adolescence: an increasing trend: 1999–2004. Arch Pediatr Adolesc Med. 160(12):1217–1222.
   PubMed Web of Science ®Google Scholar
• Burton M, Shaw L, Schentag J, Evans W. 2006. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. Philadelphia: Lippincott Williams & Wilkins.
   Google Scholar
• Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA. 1996. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther. 60(3):295–307.
   PubMed Web of Science ®Google Scholar
• Cazet L, Bulteau S, Evin A, Spiers A, Caillet P, Kuhn E, Pivette J, Chaslerie A, Jolliet P, Victorri-Vigneau C. 2018. Interaction between CYP2D6 inhibitor antidepressants and codeine: is this relevant? Expert Opin Drug Metab Toxicol. 14(8):879–886.
   PubMed Web of Science ®Google Scholar
• Chen S-L, Huang E-K, Chow L-H, Tao P-L. 2005. Dextromethorphan differentially affects opioid antinociception in rats. Br J Pharmacol. 144(3):400–404.
   PubMed Web of Science ®Google Scholar
• Chez M, Kile S, Lepage C, Parise C, Benabides B, Hankins A. 2018. A randomized, placebo-controlled, blinded, crossover, pilot study of the effects of dextromethorphan/quinidine for the treatment of neurobehavioral symptoms in adults with autism. J Autism Dev Disord. DOI:10.1007/s10803-018-3703-x.
   Web of Science ®Google Scholar
• Chou Y-C, Liao J-F, Chang W-Y, Lin M-F, Chen C-F. 1999. Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res. 821(2):516–519.
   PubMed Web of Science ®Google Scholar
• Chung HS, Choi HK, Kim EM, Park MJ, Chung KH, Yoo YC. 1998. Demographic characteristics of zipeprol-associated deaths in Korea. Arch Pharm Res. 21(3):286–290.
   PubMed Web of Science ®Google Scholar
• Church J, Jones MG, Davies SN, Lodge D. 1989. Antitussive agents as N-methylaspartate antagonists: further studies. Can J Physiol Pharmacol. 67(6):561–567.
   PubMed Web of Science ®Google Scholar
• Church J, Lodge D, Berry SC. 1985. Differential effects of dextrorphan and levorphanol on the excitation of rat spinal neurons by amino acids. Eur J Pharmacol. 111(2):185–190.
   PubMed Web of Science ®Google Scholar
• Chyka PA, Erdman AR, Manoguerra AS, Christianson G, Booze LL, Nelson LS, Woolf AD, Cobaugh DJ, Caravati EM, Scharman EJ, et al. 2007. Dextromethorphan poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 45(6):662–677.
   PubMed Web of Science ®Google Scholar
• Cochems A, Harding P, Liddicoat L. 2007. Dextromethorphan in Wisconsin drivers. J Anal Toxicol. 31(4):227–232.
   PubMed Web of Science ®Google Scholar
• Collins SR. 2018. Mosby’s drug reference for health professions. St. Louis: Elsevier, Inc.
   Google Scholar
• Cornish JW, Herman BH, Ehrman RN, Robbins SJ, Childress AR, Bead V, Esmonde CA, Martz K, Poole S, Caruso FS, et al. 2002. A randomized, double-blind, placebo-controlled safety study of high-dose dextromethorphan in methadone-maintained male inpatients. Drug Alcohol Depend. 67(2):177–183.
   PubMed Web of Science ®Google Scholar
• Coutts RT, Su P, Baker GB. 1994. Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. J Pharmacol Toxicol Methods. 31(4):177–186.
   PubMed Web of Science ®Google Scholar
• de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Cami J. 2004. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 26(2):137–144.
   PubMed Web of Science ®Google Scholar
• Dematteis M, Lallement G, Mallaret M. 1998. Dextromethorphan and dextrorphan in rats: common antitussives — different behavioural profiles. Fundam Clin Pharmacol. 12(5):526–537.
   PubMed Web of Science ®Google Scholar
• Desai S, Aldea D, Daneels E, Soliman M, Braksmajer AS, Kopes-Kerr CP. 2006. Chronic addiction to dextromethorphan cough syrup: a case report. J Am Board Fam Med. 19(3):320–323.
   PubMed Web of Science ®Google Scholar
• Desmeules JA, Oestreicher MK, Piguet V, Allaz AF, Dayer P. 1999. Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan. J Pharmacol Exp Ther. 288(2):607–612.
   PubMed Web of Science ®Google Scholar
• Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP. 2002. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci. 71(10):1149–1160.
   PubMed Web of Science ®Google Scholar
• Dickerson DL, Schaepper MA, Peterson MD, Ashworth MD. 2008. Coricidin HBP abuse: patient characteristics and psychiatric manifestations as recorded in an inpatient psychiatric unit. J Addict Dis. 27(1):25–32.
   PubMed Web of Science ®Google Scholar
• Dilich A, Girgis C. 2017. Robo-tripping: a case of robitussin abuse in a methadone maintenance patient. Psychosomatics. 58(5):544–550.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. 2016. Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response. Drug Metabol Rev. 48(4):568–576.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. 2017. Metabolism and metabolomics of ketamine: a toxicological approach. Forensic Sci Res. 2(1):2–10.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. 2019. Metabolism and metabolomics of opiates: a long way of forensic implications to unravel. J Forensic Legal Med. 61:128–140.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ, Carvalho F, Duarte JA, Dias R, Magalhães T, Santos A. 2010. Suicide by hanging under the influence of ketamine and ethanol. Forensic Sci Int. 202(1–3):e23–e27.
   PubMed Web of Science ®Google Scholar
• DuBois BN, Mehvar R. 2018. UPLC–MS/MS analysis of dextromethorphan-O-demethylation kinetics in rat brain microsomes. J Chromatogr B. 1096:66–72.
   PubMed Web of Science ®Google Scholar
• Duedahl TH, Dirks J, Petersen KB, Romsing J, Larsen N-E, Dahl JB. 2005. Intravenous dextromethorphan to human volunteers: relationship between pharmacokinetics and anti-hyperalgesic effect. Pain. 113:360–368.
   PubMed Web of Science ®Google Scholar
• Dy P, Arcega V, Ghali W, Wolfe W. 2017. Serotonin syndrome caused by drug to drug interaction between escitalopram and dextromethorphan. BMJ Case Rep. 2017:bcr2017221486.
   PubMedGoogle Scholar
• El-Naby EH, Kamel AH. 2015. Potential transducers based man-tailored biomimetic sensors for selective recognition of dextromethorphan as an antitussive drug. Mater Sci Eng C. 54:217–224.
   PubMed Web of Science ®Google Scholar
• Emancipator K, Kroll MH. 1990. Bromide interference: is less really better? Clin Chem. 36(8):1470–1473.
   PubMed Web of Science ®Google Scholar
• Farmer AD, Holt CB, Downes TJ, Ruggeri E, Del Vecchio S, De Giorgio R. 2018. Pathophysiology, diagnosis, and management of opioid-induced constipation. Lancet Gastroenterol Hepatol. 3(3):203–212.
   PubMed Web of Science ®Google Scholar
• Fluyau D, Revadigar N, Pierre CG. 2020. Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: a systematic review. Drug Alcohol Depend. 208:107845.
   PubMed Web of Science ®Google Scholar
• Forget P, de Waroux BP, Wallemacq P, Gala J-L. 2008. Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study. J Pain Symptom Manage. 36(1):92–96.
   PubMed Web of Science ®Google Scholar
• Fralick M, Sacks CA, Kesselheim AS. 2019. Assessment of use of combined dextromethorphan and quinidine in patients with dementia or Parkinson disease after US Food and Drug Administration approval for pseudobulbar affect. JAMA Intern Med. 179(2):224–230.
   PubMed Web of Science ®Google Scholar
• Frances C, Hoizey G, Lamiable D, Millart H, Trenque T. 2003. Bromism from daily over intake of bromide salt. J Toxicol Clin Toxicol. 41(2):181–183.
   PubMed Web of Science ®Google Scholar
• Franklin PH, Murray TF. 1992. High affinity [3H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-d-aspartate receptor-cation channel. Mol Pharmacol. 41(1):134–146.
   PubMed Web of Science ®Google Scholar
• Gaedigk A. 2013. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry. 25(5):534–553.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE, the PharmVar Steering Committee. 2018. The Pharmacogene Variation (PharmVar) Consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther. 103(3):399–401.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. 2017. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 19(1):69–76.
   PubMed Web of Science ®Google Scholar
• Gaikwad R, Gaonkar R, Jadhav S, Thorat V, Jadhav J, Balsara J. 2005. Involvement of central serotonergic systems in dextromethorphan-induced behavioural syndrome in rats. Indian J Exp Biol. 43(7):620–625.
   PubMedGoogle Scholar
• Gao Z, Yu L, Clark S, Trehy M, Moore T, Westenberger B, Buhse L, Kauffman J, Bishop B, Velazquez L, et al. 2015. Dissolution testing for bioavailability of over-the-counter (OTC) drugs—a technical note. AAPS PharmSciTech. 16(5):1227–1233.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. 2011. Dextromethorphan/quinidine: in pseudobulbar affect. CNS Drugs. 25(5):435–445.
   PubMed Web of Science ®Google Scholar
• Gazzaz M, Kinzig M, Schaeffeler E, Jubner M, Hsin CH, Li X, Taubert M, Trueck C, Iltgen-Breburda J, Kraus D, et al. 2018. Drinking ethanol has few acute effects on CYP2C9, CYP2C19, NAT2, and P-glycoprotein activities but somewhat inhibits CYP1A2, CYP2D6, and intestinal CYP3A: so what? Clin Pharmacol Ther. 104(6):1249–1259.
   PubMed Web of Science ®Google Scholar
• Glass SM, Leddy SM, Orwin MC, Miller GP, Furge KA, Furge LL. 2019. Rolapitant is a reversible inhibitor of CYP2D6. Drug Metab Dispos. 47(6):567–573.
   PubMed Web of Science ®Google Scholar
• Glick SD, Maisonneuve IM, Dickinson HA, Kitchen BA. 2001. Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats. Eur J Pharmacol. 422(1–3):87–90.
   PubMed Web of Science ®Google Scholar
• Grattan T, Marshall A, Higgins K, Morice A. 1995. The effect of inhaled and oral dextromethorphan on citric acid induced cough in man. Br J Clin Pharmacol. 39(3):261–263.
   PubMed Web of Science ®Google Scholar
• Gudin J, Fudin J, Nalamachu S. 2016. Levorphanol use: past, present and future. Postgrad Med. 128(1):46–53.
   PubMed Web of Science ®Google Scholar
• Gunn VL, Taha SH, Liebelt EL, Serwint JR. 2001. Toxicity of over-the-counter cough and cold medications. Pediatrics. 108(3):e52.
   PubMed Web of Science ®Google Scholar
• Gutierrez Rico EM, Kikuchi A, Saito T, Kumondai M, Hishinuma E, Kaneko A, Chan CW, Gitaka J, Nakayoshi T, Oda A, et al. 2020. CYP2D6 genotyping analysis and functional characterization of novel allelic variants in a Ni-Vanuatu and Kenyan population by assessing dextromethorphan O-demethylation activity. Drug Metab Pharmacokinet. 35(1):89–101.
   PubMed Web of Science ®Google Scholar
• Hart M, Agnich LE, Stogner J, Miller BL. 2014. ‘Me and My Drank:’ exploring the relationship between musical preferences and purple drank experimentation. Am J Crim Just. 39(1):172–186.
   Google Scholar
• Hendrickson RG, Cloutier RL. 2007. “Crystal dex:” free-base dextromethorphan. J Emerg Med. 32(4):393–396.
   PubMed Web of Science ®Google Scholar
• Hou ZY, Pickle LW, Meyer PS, Woosley RL. 1991. Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther. 49(4):410–419.
   PubMed Web of Science ®Google Scholar
• Hou C-H, Tzeng J-I, Chen Y-W, Lin C-N, Lin M-T, Tu C-H, Wang J-J. 2006. Dextromethorphan, 3-methoxymorphinan, and dextrorphan have local anaesthetic effect on sciatic nerve blockade in rats. Eur J Pharmacol. 544(1–3):10–16.
   PubMed Web of Science ®Google Scholar
• Howden CW, Birnie GG, Brodie MJ. 1989. Drug metabolism in liver disease. Pharmacol Ther. 40(3):439–474.
   PubMed Web of Science ®Google Scholar
• Hsieh PF, Tsan YT, Hung DZ, Hsu CL, Lee YC, Chang MH. 2007. Bromism caused by mix-formulated analgesic injectables. Hum Exp Toxicol. 26(12):971–973.
   PubMed Web of Science ®Google Scholar
• Hung Y-M. 2003. Bromide intoxication by the combination of bromide-containing over-the-counter drug and dextromethorphan hydrobromide. Hum Exp Toxicol. 22(8):459–461.
   PubMed Web of Science ®Google Scholar
• Ishmael JE, Franklin PH, Murray TF. 1998. Dextrorotatory opioids induce stereotyped behavior in Sprague-Dawley and Dark Agouti rats. Psychopharmacology. 140(2):206–216.
   PubMed Web of Science ®Google Scholar
• Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. 1993. CYP2D6-and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics. 3:197–204.
   PubMedGoogle Scholar
• James LP, Farrar HC, Griebel ML, Bates SR. 1997. Bromism: intoxication from a rare anticonvulsant therapy. Pediatr Emerg Care. 13(4):268–270.
   PubMed Web of Science ®Google Scholar
• Jasinski DR. 2000. Abuse potential of morphine/dextromethorphan combinations. J Pain Symptom Manage. 19(1):S26–S30.
   PubMed Web of Science ®Google Scholar
• Jayachandra S, Sethi MK, Mahajan S, Singh KS, Mara B, Chakraborty P. 2018. Preparation of morphine derivatives using ionic liquids. Arc Org Inorg Chem Sci. 3(2):ID: 000156. DOI:10.32474/AOICS.2018.03.000156
   Google Scholar
• Jetter A, Fatkenheuer G, Frank D, Klaassen T, Seeringer A, Doroshyenko O, Kirchheiner J, Hein W, Schomig E, Fuhr U, et al. 2010. Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antivir Ther. 15(7):975–983.
   PubMed Web of Science ®Google Scholar
• Kamei J. 1996. Role of opioidergic and serotonergic mechanisms in cough and antitussives. Pulm Pharmacol. 9(5–6):349–356.
   PubMedGoogle Scholar
• Kanaan M, Daali Y, Dayer P, Desmeules J. 2008. Lack of interaction of the NMDA receptor antagonists dextromethorphan and dextrorphan with P-glycoprotein. Curr Drug Metab. 9(2):144–151.
   PubMed Web of Science ®Google Scholar
• Kaplan B, Buchanan J, Krantz MJ. 2011. QTc prolongation due to dextromethorphan. Int J Cardiol. 148(3):363–364.
   PubMed Web of Science ®Google Scholar
• Karami S, Major JM, Calderon S, McAninch JK. 2018. Trends in dextromethorphan cough and cold products: 2000–2015 National Poison Data System intentional abuse exposure calls. Clin Toxicol. 56(7):656–663.
   PubMed Web of Science ®Google Scholar
• Karch SB. 2008. Pharmacokinetics and pharmacodynamics of abused drugs. Boca Raton (FL): CRC Press.
   Google Scholar
• Karch SB, Drummer OH. 2016. Karch’s pathology of drug abuse. Boca Raton: CRC Press, Taylor & Francis Group.
   Google Scholar
• Kazis A, Kimiskidis V, Niopas I. 2009. Pharmacokinetics of dextromethorphan and dextrorphan in epileptic patients. Acta Neurol Scand. 93(2–3):94–98.
   Google Scholar
• Kerry N, Somogyi A, Bochner F, Mikus G. 1994. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol. 38(3):243–248.
   PubMed Web of Science ®Google Scholar
• Kinoshita H, Ohkubo T, Yasuda M, Yakushiji F. 2011. Serotonin syndrome induced by dextromethorphan (Medicon) administrated at the conventional dose. Geriatr Gerontol Int. 11(1):121–122.
   PubMed Web of Science ®Google Scholar
• Kintz P, Mangin P. 1992. Toxicological findings in a death involving dextromethorphan and terfenadine. Am J Forensic Med Pathol. 13:351–352.
   PubMed Web of Science ®Google Scholar
• Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. 1997. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 25:853–862.
   PubMed Web of Science ®Google Scholar
• Kongpakwattana K, Sawangjit R, Tawankanjanachot I, Bell JS, Hilmer SN, Chaiyakunapruk N. 2018. Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis. Br J Clin Pharmacol. 84(7):1445–1456.
   PubMed Web of Science ®Google Scholar
• Kunze U. 1976. Chronic bromide intoxication with a severe neurological deficit. J Neurol. 213(2):149–152.
   PubMed Web of Science ®Google Scholar
• Küpfer A, Preisig R. 1983. Inherited defects of hepatic drug metabolism. Semin Liver Dis. 3(4):341–354.
   PubMed Web of Science ®Google Scholar
• Larrey D, Amouyal G, Tinel M, Letteron P, Berson A, Labbe G, Pessayre D. 1987. Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol. 24(5):676–679.
   PubMed Web of Science ®Google Scholar
• Larrey D, Babany G, Tinel M, Freneaux E, Amouyal G, Habersetzer F, Letteron P, Pessayre D. 1989. Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients. Br J Clin Pharmacol. 28(3):297–304.
   PubMed Web of Science ®Google Scholar
• Le Rouzic V, Narayan A, Hunkle A, Marrone GF, Lu Z, Majumdar S, Xu J, Pan Y-X, Pasternak GW. 2019. Pharmacological characterization of levorphanol, a G-protein biased opioid analgesic. Anesth Analg. 128(2):365–373.
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Chen S-L, Chang Y-H, Chu C-H, Chen S-H, Chen PS, Huang S-Y, Tzeng N-S, Wang L-J, Lee IH, et al. 2015. A placebo-controlled trial of dextromethorphan as an adjunct in opioid-dependent patients undergoing methadone maintenance treatment. Int J Neuropsychopharmacol. 18(7):pyv008.
   PubMed Web of Science ®Google Scholar
• Logan BK. 2009. Combined dextromethorphan and chlorpheniramine intoxication in impaired drivers. J Forensic Sci. 54(5):1176–1180.
   PubMed Web of Science ®Google Scholar
• Logan BK, Goldfogel G, Hamilton R, Kuhlman J. 2009. Five deaths resulting from abuse of dextromethorphan sold over the internet. J Anal Toxicol. 33(2):99–103.
   PubMed Web of Science ®Google Scholar
• Logan BK, Yeakel JK, Goldfogel G, Frost MP, Sandstrom G, Wickham DJ. 2012. Dextromethorphan abuse leading to assault, suicide, or homicide. J Forensic Sci. 57(5):1388–1394.
   PubMed Web of Science ®Google Scholar
• Lotrich FE, Rosen J, Pollock BG. 2005. Dextromethorphan-induced delirium and possible methadone interaction. Am J Geriatr Pharmacother. 3(1):17–20.
   PubMedGoogle Scholar
• Loyd V, Allen J, Ansel HC. 2014. Ansel’s pharmaceutical dosage forms and drug delivery systems. Philadelphia: Lippincott Williams & Wilkins.
   Google Scholar
• Lutz JD, Isoherranen N. 2012. Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole. Drug Metab Dispos. 40(1):159–168.
   PubMed Web of Science ®Google Scholar
• Maffeis L, Musolino MC, Cambiaghi S. 2008. Single-plaque vegetating bromoderma. J Am Acad Dermatol. 58(4):682–684.
   PubMed Web of Science ®Google Scholar
• Marier J-F, Deschênes J-L, Hage A, Seliniotakis E, Gritsas A, Flarakos T, Beaudry F, Vachon P. 2005. Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil. Life Sci. 77(23):2911–2926.
   PubMed Web of Science ®Google Scholar
• Marinetti L, Lehman L, Casto B, Harshbarger K, Kubiczek P, Davis J. 2005. Over-the-counter cold medications—postmortem findings in infants and the relationship to cause of death. J Anal Toxicol. 29(7):738–743.
   PubMed Web of Science ®Google Scholar
• Martinak B, Bolis RA, Black JR, Re F, Birur B. 2017. Dextromethorphan in cough syrup: the poor man’s psychosis. Psychopharmacol Bull. 47:59–63.
   PubMedGoogle Scholar
• McQueen C. 2017. Comprehensive toxicology. 3rd ed. Amsterdam: Elsevier Science.
   Google Scholar
• Meoni P, Tortella F, Bowery N. 1997. An autoradiographic study of dextromethorphan high-affinity binding sites in rat brain: sodium-dependency and colocalization with paroxetine. Br J Pharmacol. 120(7):1255–1262.
   PubMed Web of Science ®Google Scholar
• Meyer UA, Skoda RC, Zanger UM. 1990. The genetic polymorphism of debrisoquine/sparteine metabolism—molecular mechanisms. Pharmacol Ther. 46(2):297–308.
   PubMed Web of Science ®Google Scholar
• Miller S. 2005. Dextromethorphan psychosis, dependence and physical withdrawal. Addict Biol. 10(4):325–327.
   PubMed Web of Science ®Google Scholar
• Morrison LM, Unger KA, Watterson JH. 2017. Analysis of dextromethorphan and dextrorphan in skeletal remains following differential microclimate exposure: comparison of acute vs. repeated drug exposure. J Anal Toxicol. 41(6):566–572.
   PubMed Web of Science ®Google Scholar
• Mortimer O, Lindstrom B, Laurell H, Bergman U, Rane A. 1989. Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. Br J Clin Pharmacol. 27(2):223–227.
   PubMed Web of Science ®Google Scholar
• Moss MJ, Hendrickson RG, Toxicology Investigators C. 2019. Serotonin toxicity: associated agents and clinical characteristics. J Clin Psychopharmacol. 39(6):628–633.
   PubMed Web of Science ®Google Scholar
• Nagai N, Kawakubo T, Kaneko F, Ishii M, Shinohara R, Saito Y, Shimamura H, Ohnishi A, Ogata H. 1996. Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population. Biopharm Drug Dispos. 17(5):421–433.
   PubMed Web of Science ®Google Scholar
• Netzer R, Pflimlin P, Trube G. 1993. Dextromethorphan blocks N-methyl-d-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. Eur J Pharmacol. 238(2–3):209–216.
   PubMed Web of Science ®Google Scholar
• Ng YY, Lin WL, Chen TW, Lin BC, Tsai SH, Chang CC, Huang TP. 1992. Spurious hyperchloremia and decreased anion gap in a patient with dextromethorphan bromide. Am J Nephrol. 12(4):268–270.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Robson MJ, Healy JR, Scandinaro AL, Matsumoto RR. 2014. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS One. 9(2):e89985.
   PubMed Web of Science ®Google Scholar
• Nicholson KL, Hayes BA, Balster RL. 1999. Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology (Berl). 146(1):49–59.
   PubMed Web of Science ®Google Scholar
• O’Mathuna B, Farre M, Rostami-Hodjegan A, Yang J, Cuyas E, Torrens M, Pardo R, Abanades S, Maluf S, Tucker GT, et al. 2008. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol. 28:523–529.
   PubMed Web of Science ®Google Scholar
• Oda F, Tohyama M, Murakami A, Kanno K, Sonobe N, Sayama K. 2016. Bromoderma mimicking pyoderma gangrenosum caused by commercial sedatives. J Dermatol. 43(5):564–566.
   PubMed Web of Science ®Google Scholar
• Olives TD, Boley SP, LeRoy JM, Stellpflug SJ. 2019. Ten years of robotripping: evidence of tolerance to dextromethorphan hydrobromide in a long-term user. J Med Toxicol. 15(3):192–197.
   PubMed Web of Science ®Google Scholar
• Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. 1996. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 41(2):149–156.
   PubMed Web of Science ®Google Scholar
• Parks KA, Kennedy CL. 2004. Club drugs: reasons for and consequences of use. J Psychoact Drugs. 36(3):295–302.
   PubMed Web of Science ®Google Scholar
• Pechnick RN, Poland RE. 2004. Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 309(2):515–522.
   PubMed Web of Science ®Google Scholar
• Pfaff G, Briegel P, Lamprecht I. 1983. Inter-individual variation in the metabolism of dextromethorphan. Int J Pharm. 14(2–3):173–189.
   Web of Science ®Google Scholar
• Pickering G, Pereira B, Morel V, Tiberghien F, Martin E, Marcaillou F, Picard P, Delage N, de Montgazon G, Sorel M, et al. 2014. Rationale and design of a multicenter randomized clinical trial with memantine and dextromethorphan in ketamine-responder patients. Contemp Clin Trials. 38(2):314–320.
   PubMed Web of Science ®Google Scholar
• Poklis JL, Mulder HA, Peace MR. 2019. The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids. Forensic Sci Int. 294:e25–e27.
   PubMed Web of Science ®Google Scholar
• Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ, Sellers EM. 2004. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol. 44(10):1132–1142.
   PubMed Web of Science ®Google Scholar
• Ramachander G, Williams FD, Emele JF. 1977. Determination of dextrorphan in plasma and evaluation of bioavailability of dextromethorphan hydrobromide in humans. J Pharm Sci. 66(7):1047–1048.
   PubMed Web of Science ®Google Scholar
• Rammer L, Holmgren P, Sandler H. 1988. Fatal intoxication by dextromethorphan: a report on two cases. Forensic Sci Int. 37(4):233–236.
   PubMed Web of Science ®Google Scholar
• Ramsay J, Wright C, Thompson R, Hull D, Morice AH. 2008. Assessment of antitussive efficacy of dextromethorphan in smoking related cough: objective vs. subjective measures. Br J Clin Pharmacol. 65(5):737–741.
   PubMed Web of Science ®Google Scholar
• Repetto MR, Repetto M. 1998. Therapeutic, toxic, and lethal concentrations of 73 drugs affecting respiratory system in human fluids. J Toxicol Clin Toxicol. 36(4):287–293.
   PubMed Web of Science ®Google Scholar
• Repetto MR, Repetto M. 1999. Concentrations in human fluids: 101 drugs affecting the digestive system and metabolism. J Toxicol Clin Toxicol. 37(1):1–9.
   PubMed Web of Science ®Google Scholar
• Ritter D, Ouellette L, Sheets JD, Riley B, Judge B, Cook A, Houseman J, Jones JS. 2019. “Robo-tripping”: dextromethorphan toxicity and abuse. Am J Emerg Med. DOI:10.1016/j.ajem.2019.10.001
   Web of Science ®Google Scholar
• Rodrigues WC, Wang G, Moore C, Agrawal A, Vincent MJ, Soares JR. 2008. Development and validation of ELISA and GC–MS procedures for the quantification of dextromethorphan and its main metabolite dextrorphan in urine and oral fluid. J Anal Toxicol. 32(3):220–226.
   PubMed Web of Science ®Google Scholar
• Romanelli F, Smith KM. 2009. Dextromethorphan abuse: clinical effects and management. J Am Pharm Assoc. 49(2):e20–e25.
   Google Scholar
• Roos FJ, Zysset T, Reichen J. 1991. Differential effect of biliary and micronodular cirrhosis on oxidative drug metabolism: in vivo–in vitro correlations of dextromethorphan metabolism in rat models. Biochem Pharmacol. 41(10):1513–1519.
   PubMed Web of Science ®Google Scholar
• Sawynok J, Reid A. 2003. Peripheral interactions between dextromethorphan, ketamine and amitriptyline on formalin-evoked behaviors and paw edema in rats. Pain. 102(1–2):179–186.
   PubMed Web of Science ®Google Scholar
• Schadel M, Wu D, Otton SV, Kalow W, Sellers EM. 1995. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol. 15(4):263–269.
   PubMed Web of Science ®Google Scholar
• Schmid B, Bircher J, Preisig R, Küpfer A. 1985. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther. 38(6):618–624.
   PubMed Web of Science ®Google Scholar
• Schoedel KA, Pope LE, Sellers EM. 2012. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. Clin Drug Investig. 32(3):157–169.
   PubMed Web of Science ®Google Scholar
• Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A. 2012. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care. 16(4):R136.
   PubMed Web of Science ®Google Scholar
• Schwartz RH. 2005. Adolescent abuse of dextromethorphan. Clin Pediatr (Phila). 44(7):565–568.
   PubMed Web of Science ®Google Scholar
• Shafi H, Imran M, Usman HF, Sarwar M, Tahir MA, Naveed R, Ashiq MZ, Tahir AM. 2016. Deaths due to abuse of dextromethorphan sold over-the-counter in Pakistan. Egypt J Forensic Sci. 6(3):280–283.
   Google Scholar
• Shi T, Hao J-X, Wiesenfeld-Hallin Z, Xu X-J. 2018. Gabapentin and NMDA receptor antagonists interacts synergistically to alleviate allodynia in two rat models of neuropathic pain. Scand J Pain. 18(4):687–693.
   PubMed Web of Science ®Google Scholar
• Shin EJ, Nah SY, Kim WK, Ko KH, Jhoo WK, Lim YK, Cha JY, Chen CF, Kim HC. 2005. The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via σ1 receptor activation: comparison with the effects of dextromethorphan. Br J Pharmacol. 144(7):908–918.
   PubMed Web of Science ®Google Scholar
• Solimini R, Rotolo MC, Pellegrini M, Minutillo A, Pacifici R, Busardò FP, Zaami S. 2017. Adulteration practices of psychoactive illicit drugs: an updated review. Curr Pharm Biotechnol. 18(7):524–530.
   PubMed Web of Science ®Google Scholar
• Spangler DC, Loyd CM, Skor EE. 2016. Dextromethorphan: a case study on addressing abuse of a safe and effective drug. Subst Abuse Treat Prev Policy. 11(1):22.
   PubMed Web of Science ®Google Scholar
• Sromek AW, Provencher BA, Russell S, Chartoff E, Knapp BI, Bidlack JM, Neumeyer JL. 2014. Preliminary pharmacological evaluation of enantiomeric morphinans. ACS Chem Neurosci. 5(2):93–99.
   PubMed Web of Science ®Google Scholar
• Stanciu CN, Penders TM, Rouse EM. 2016. Recreational use of dextromethorphan, “Robotripping”—a brief review. Am J Addict. 25(5):374–377.
   PubMed Web of Science ®Google Scholar
• Steinberg GK, Kunis D, DeLaPaz R, Poljak A. 1993. Neuroprotection following focal cerebral ischaemia with the NMDA antagonist dextromethorphan, has a favourable dose response profile. Neurol Res. 15(3):174–180.
   PubMed Web of Science ®Google Scholar
• Strauch K, Lutz U, Bittner N, Lutz WK. 2009. Dose-response relationship for the pharmacokinetic interaction of grapefruit juice with dextromethorphan investigated by human urinary metabolite profiles. Food Chem Toxicol. 47(8):1928–1935.
   PubMed Web of Science ®Google Scholar
• Szekely JI, Sharpe LG, Jaffe JH. 1991. Induction of phencyclidine-like behavior in rats by dextrorphan but not dextromethorphan. Pharmacol Biochem Behav. 40(2):381–386.
   PubMed Web of Science ®Google Scholar
• Takashima T, Murase S, Iwasaki K, Shimada K. 2005. Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers. Drug Metab Pharmacokinet. 20(3):177–182.
   PubMedGoogle Scholar
• Tanaka A, Nagamatsu T, Yamaguchi M, Nomura A, Nagura F, Maeda K, Tornino T, Watanabe T, Shimizu H, Fujita Y, et al. 2011. Myoclonus after dextromethorphan administration in peritoneal dialysis. Ann Pharmacother. 45(1):123.
   Google Scholar
• Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y. 2000. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys. 378(2):356–363.
   PubMed Web of Science ®Google Scholar
• Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. 2016. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta(R)) clinical use. Pharmacol Ther. 164:170–182.
   PubMed Web of Science ®Google Scholar
• Tornio A, Filppula AM, Niemi M, Backman JT. 2019. Clinical studies on drug–drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clin Pharmacol Ther. 105(6):1345–1361.
   PubMed Web of Science ®Google Scholar
• Uhr M, Namendorf C, Grauer MT, Rosenhagen M, Ebinger M. 2004. P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6. J Psychopharmacol. 18(4):509–515.
   PubMed Web of Science ®Google Scholar
• Unger KA, Watterson JH. 2016. Analysis of dextromethorphan and dextrorphan in skeletal remains following decomposition in different microclimate conditions. J Anal Toxicol. 40(8):669–676.
   PubMed Web of Science ®Google Scholar
• Vanamala J, Cobb G, Turner ND, Lupton JR, Yoo KS, Pike LM, Patil BS. 2005. Bioactive compounds of grapefruit (Citrus paradisi Cv. Rio Red) respond differently to postharvest irradiation, storage, and freeze drying. J Agric Food Chem. 53(10):3980–3985.
   PubMed Web of Science ®Google Scholar
• Wang SC, Chou DT, Wallenstein MC. 1977. Studies on the potency of various antitussive agents. Agents Actions. 7(3):337–340.
   PubMedGoogle Scholar
• Wang J, Mack AL, Coop A, Matsumoto RR. 2007. Novel sigma (σ) receptor agonists produce antidepressant-like effects in mice. Eur Neuropsychopharmacol. 17(11):708–716.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang ZY, Lu S, Powers D, Kansra V, Wang X. 2019. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects. Support Care Cancer. 27(3):819–827.
   PubMed Web of Science ®Google Scholar
• Werling LL, Keller A, Frank JG, Nuwayhid SJ. 2007. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 207(2):248–257.
   PubMed Web of Science ®Google Scholar
• WHO. 2012. Dextromethorphan: pre-review report. Hammamet: World Health Organization.
   Google Scholar
• Wolfe TR, Caravati EM. 1995. Massive dextromethorphan ingestion and abuse. Am J Emerg Med. 13(2):174–176.
   PubMed Web of Science ®Google Scholar
• Wong BY, Coulter DA, Choi DW, Prince DA. 1988. Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-d-aspartate in brain slices. Neurosci Lett. 85(2):261–266.
   PubMed Web of Science ®Google Scholar
• Wong SHY, Sunshine I. 1996. Handbook of analytical therapeutic drug monitoring and toxicology. New York: Taylor & Francis.
   Google Scholar
• Woo TM, Hanley JR. 2013. “How high do they look?”: identification and treatment of common ingestions in adolescents. J Pediatr Health Care. 27(2):135–144.
   PubMed Web of Science ®Google Scholar
• Woodworth JR, Dennis SR, Hinsvark ON, Amsel LP, Rotenberg KS. 1987. Bioavailability evaluation of a controlled-release dextromethorphan liquid. J Clin Pharmacol. 27(2):133–138.
   PubMed Web of Science ®Google Scholar
• Wu D, Otton SV, Kalow W, Sellers EM. 1995. Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat. J Pharmacol Exp Ther. 274:1431–1437.
   PubMed Web of Science ®Google Scholar
• Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, Seeringer A, Doroshyenko O, Kirchheiner JC, Abdulrazik F, et al. 2008. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther. 84(1):75–82.
   PubMed Web of Science ®Google Scholar
• Yeh G-C, Tao P-L, Ho H-O, Lee Y-J, Chen J-R, Sheu M-T. 2003. Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes. J Biomed Sci. 10(5):552–564.
   PubMed Web of Science ®Google Scholar
• Yoo Y, Chung H, Kim E, Kim M. 1996. Fatal zipeprol and dextromethorphan poisonings in Korea. J Anal Toxicol. 20(3):155–158.
   PubMed Web of Science ®Google Scholar
• Yu A, Haining RL. 2001. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos. 29:1514–1520.
   PubMed Web of Science ®Google Scholar
• Yubero-Lahoz S, Pardo R, Farré M, O'Mahony B, Torrens M, Mustata C, Pérez-Mañá C, Carbó ML, de la Torre R. 2011. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin Pharmacokinet. 50(5):319–329.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Raimundo S, Eichelbaum M. 2004. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg’s Arch Pharmacol. 369(1):23–37.
   Google Scholar
• Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM. 1998. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. J Clin Psychopharmacol. 18(4):332–337.
   PubMed Web of Science ®Google Scholar
• Zawertailo LA, Tyndale RF, Busto U, Sellers EM. 2010. Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Hum Psychopharmacol Clin Exp. 25(1):71–79.
   PubMed Web of Science ®Google Scholar
• Zhou SF. 2009a. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 48(11):689–723.
   PubMed Web of Science ®Google Scholar
• Zhou SF. 2009b. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 48(12):761–804.
   PubMed Web of Science ®Google Scholar
• Zhou H, Meibohm B. 2013. Drug–drug interactions for therapeutic biologics. New York: John Wiley & Sons Inc.
   Google Scholar
• Zysset T, Zeugin T, Küpfer A. 1988. In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man. Biochem Pharmacol. 37(16):3155–3160.
   PubMed Web of Science ®Google Scholar